Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06656494 · ClinicalTrials.gov registry record · Phase 1

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

A Phase 1 study of Acute Myelogenous Leukemia and Myelodysplastic Syndromes (MDS), sponsored by Beijing InnoCare Pharma Tech Co..

Recruiting
Registry status
Phase 1
Development phase
266
Enrollment target
15
Study locations

NCT06656494 is a Phase 1 study of Acute Myelogenous Leukemia and Myelodysplastic Syndromes (MDS) that is actively recruiting participants, run by Beijing InnoCare Pharma Tech Co.. The registered enrollment target is 266 participants, above the 133-participant average among 38 other Acute Myelogenous Leukemia trials with a reported enrollment target (100% higher). The trial reports 15 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06656494, a Phase 1 study of Acute Myelogenous Leukemia and Myelodysplastic Syndromes (MDS), is actively recruiting participants, sponsored by Beijing InnoCare Pharma Tech Co..

RECRUITING
Registry status
Phase 1
Development phase
266 participants
Enrollment target
15
Study locations

Study Summary

Evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ICP-248 in combination with azacitidine in patients with acute myelogenous leukemia and Myelodysplastic Syndromes.

Conditions Studied

Acute Myelogenous Leukemia Myelodysplastic Syndromes (MDS)

Interventions

  • DRUG Azacitidine
  • DRUG ICP-248

Study Locations (15)

Guangdong

  • Guangdong Provincial People's Hospital - Guangzhou
  • Nanfang Hospital Southern Medical University - Guangzhou

New York

  • NYU Langone Health - New York

Anhui

  • Anhui Provincial Hospita - Hefei

Beijing Municipality

  • Peking University People's Hospital - Beijing

Chongqing Municipality

  • The First Affiliated Hospital of Chongqing Medical University - Chongqing

Henan

  • Henan Cancer Hospital - Zhengzhou

Hubei

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology - Wuhan

Jiangsu

  • The First Affiliated Hospital of Soochow University - Suzhou

Trial Details

FieldValue
Enrollment Target 266 participants
Start Date 2024-12-18
Est. Completion 2028-01
Phase Phase 1

Sponsor

Beijing InnoCare Pharma Tech Co.

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06656494

The ClinicalTrials.gov registry entry for NCT06656494 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 266 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 133-participant average among 38 other Acute Myelogenous Leukemia trials with a reported enrollment target (100% higher). The listed sponsor is Beijing InnoCare Pharma Tech Co., which has 3 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Acute Myelogenous Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Azacitidine is the first listed.

NCT06656494 reports 15 study locations spanning 14 distinct geographic areas - top geographies include Guangdong, New York, Anhui.

Frequently Asked Questions

What is clinical trial NCT06656494 about?

NCT06656494 is a clinical study titled "ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies". Evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ICP-248 in combination with azacitidine in patients with acute myelogenous leukemia and Myelodysplastic Syndromes.

What is the current status of trial NCT06656494?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 266 participants. The study started on 2024-12-18. Estimated completion is 2028-01.

What conditions does trial NCT06656494 study?

This clinical trial studies the following conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS).

What interventions are being tested in trial NCT06656494?

The interventions under investigation include: Azacitidine (DRUG), ICP-248 (DRUG).

Who is sponsoring clinical trial NCT06656494?

This trial is sponsored by Beijing InnoCare Pharma Tech Co., which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06656494 being conducted?

This trial has 15 study locations across New York, Anhui, Beijing Municipality, Chongqing Municipality, Guangdong. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myelogenous Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Myelogenous Leukemia

All registered trials for this condition

Myelodysplastic Syndromes (MDS)

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.